Category: Metabolic Therapeutics
GLP-1, GIP, glucagon and related metabolic research programmes, mechanisms and clinical evidence.
Weight Regain After Stopping GLP-1 Medicines: What Trials Show
Compare STEP 1, STEP 4 and SURMOUNT-4 withdrawal findings, their study timelines and weight-change denominators, and limits on predicting individual regain.
Read analysis →Semaglutide and Kidney Disease: What the FLOW Trial Shows
FLOW tested semaglutide in 3,533 adults with type 2 diabetes and chronic kidney disease. Read the kidney outcomes, evidence limits and Australian TGA status.
Read analysis →CagriSema Trial Results: What REDEFINE 1 and REDEFINE 2 Actually Show
CagriSema combines cagrilintide and semaglutide. Read the phase 3 REDEFINE 1 and 2 results, analysis methods, safety findings and evidence limits.
Read analysis →MASH and MASLD Drug Evidence: FDA Decisions and Trial Tracker
Track MASH drug evidence across FDA decisions and primary trials, with biopsy endpoints, analysis populations and confirmatory-outcome limits kept separate.
Read analysis →Amylin vs GLP-1: CagriSema and Emerging Obesity Drugs
Understand how amylin and GLP-1 targets differ, what CagriSema combines, and what published cagrilintide, petrelintide and eloralintide trials show.
Read analysis →Oral GLP-1 Medicines: Approval and Clinical-Trial Evidence Tracker
Compare FDA decisions and primary trial evidence for oral semaglutide and orforglipron, with dates, trial identifiers and clear limits on comparisons.
Read analysis →What Is GLP-1? The Hormone, Receptor and Medicines Explained
A source-linked explanation of GLP-1 biology, the difference between a hormone and receptor agonist, and how to interpret single, dual and triple receptor claims.
Read analysis →Ozempic vs Wegovy Australia (2026): TGA Approval and PBS Differences
Short answer (checked 7 October 2026): Ozempic and Wegovy both contain semaglutide, but they are not the same Australian regulatory or PBS proposition. The TGA describes…
Read analysis →Wegovy PBS Australia (2026): Is Semaglutide Listed Yet?
Current answer (checked 7 October 2026): Wegovy is TGA-approved in Australia for chronic weight management, and PBAC recommended a restricted PBS listing for a defined group…
Read analysis →Mounjaro PBS Australia 2026: Listing Status & Negotiations
Current answer — checked 8 October 2026: Mounjaro (tirzepatide) is TGA-approved in Australia for type 2 diabetes and chronic weight management, but it is not currently…
Read analysis →